-- Should be easily obtained, quantitatively and qualitatively measurable, and historically applicable. -- Identify areas for major improvement, determine the amount of change required, provide motivation for change, and provide the basis for monitoring and tracking results. -- Help people understand if their probability assessments, cycle times, forecasts, and other key projections are overly optimistic or conservative. -- Enable senior managers to see intended and unintended consequences of the company's R&D strategy.SCHEDULED R&D MANAGEMENT ROUNDTABLES Upcoming Tufts CSDD Roundtable meetings in 2008 will focus on the following:
-- Sept. 11 - Optimizing Protocol Design -- Strategies to Improve Clinical Research Performance -- Nov. 6 - Assessing Change and Opportunity in the Phase I LandscapeTo register, call 617-636-2170. ABOUT THE TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. A core element of the center's educational efforts, the Tufts CSDD Institute for Professional Development, produces the Executive Forum Roundtable Series, along with postgraduate level courses, training workshops, symposia, and public forums.
Contact Information: Contact: Tufts Center for the Study of Drug Development Charlene Neu 617-636-2187 Business Communication Strategies Peter Lowy 617-734-9980